AIM ImmunoTech (AIM) FCF Margin (2010 - 2026)
AIM ImmunoTech's (AIM) quarterly FCF Margin came in at 12359.09% in Q1 2026, up 239716.0% YoY from N/an in Q1 2025, and down 30.69% on a QoQ basis from 9457.14% in Q4 2025.
AIM ImmunoTech (AIM) FCF Margin (2010 - 2026) Analysis & Trends
AIM ImmunoTech (AIM) has 17 years of FCF Margin data on file, last reported at 12359.09% in Q1 2026.
- Quarterly FCF Margin rose 239716.0% year-over-year to 12359.09% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 12037.23% (down 352080.0% YoY) and the FY2025 annual result came in at 12451.14%, down 368290.0% from the prior year.
- FCF Margin retreated to 12359.09% in Q1 2026, from 9457.14% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 5138.1% in Q2 2023 to a low of 23657.14% in Q3 2022.
- A 5-year average of 11088.84% and a median of 9457.14% in 2025 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2022 — FCF Margin plunged 1315714 bps — and 2023, when it surged 1132888 bps.
- Tracing AIM's FCF Margin over 5 years: stood at 10837.5% in 2022, then tumbled by 39 bps to 15012.31% in 2023, then surged by 41 bps to 8788.89% in 2024, then dropped by 8 bps to 9457.14% in 2025, then sank by 31 bps to 12359.09% in 2026.
- The last three FCF Margin figures came in at 12359.09% (Q1 2026), 9457.14% (Q4 2025), and 19534.62% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.53 Bn | 130.68 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 86.34 Bn | 78.35 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.67 Bn | 59.48 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.04 Bn | 53.90 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 42.03 Bn | 36.94 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 30.78 Bn | 27.47 Bn | 992.69 Mn | 22.62% |
| 7 | BioNTech SE | 27.81 Bn | 9.42 Bn | 668.28 Mn | 41.07% |
| 8 | Insmed | 27.21 Bn | 26.05 Bn | 358.27 Mn | -22.35% |
| 9 | Royalty Pharma | 26.99 Bn | 26.15 Bn | - | 70.82% |
| 10 | AIM ImmunoTech | 4.36 Mn | -5.61 Mn | 21,000.00 | -17,653.85% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -17,653.85% |
| Mar 31, 2026 | -12,359.09% |
| Dec 31, 2025 | -9,457.14% |
| Sep 30, 2025 | -19,534.62% |
| Jun 30, 2025 | -6,124.00% |
| Mar 31, 2025 | -14,756.25% |
| Dec 31, 2024 | -8,788.89% |
| Sep 30, 2024 | -8,885.71% |
| Jun 30, 2024 | -6,016.00% |
| Mar 31, 2024 | -12,037.50% |
| Dec 31, 2023 | -15,012.31% |
| Sep 30, 2023 | -12,328.26% |
| Jun 30, 2023 | -5,138.10% |
| Mar 31, 2023 | -7,510.20% |
| Dec 31, 2022 | -10,837.50% |
| Sep 30, 2022 | -23,657.14% |
| Jun 30, 2022 | -7,710.00% |
| Mar 31, 2022 | -8,357.58% |
| Dec 31, 2021 | -11,504.00% |
| Sep 30, 2021 | -10,500.00% |